Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

被引：3
|
作者：
Greaves, Wayne [1 ]
Wan, Hong [2 ]
Yee, Ka Lai [3 ]
Kandala, Bhargava [3 ]
Vaddady, Pavan [3 ]
Hwang, Carey [1 ]
机构：
[1] Merck & Co Inc, Global Clin Dev Infect Dis, Kenilworth, NJ 07033 USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Kenilworth, NJ USA
[3] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
HIV-1; doravirine; efavirenz; efficacy; pharmacokinetics;
D O I：
10.1128/AAC.01298-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
    Huang, Wei-Chieh
    Huang, Chun-Kai
    Huang, Sung-Hsi
    Lin, Shu-Wen
    Ou, Shyh-Tyan
    Chen, Yi-Ting
    Chen, Ya-Wen
    Chang, Shu-Yuan
    Liu, Wen-Chun
    Sun, Hsin-Yun
    Hung, Chien-Ching
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (05) : 944 - 951
  • [22] The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection
    Dubrocq, Gueorgui
    Rakhmanina, Natella
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 773 - 779
  • [23] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Zolopa, Andrew
    Sax, Paul E.
    DeJesus, Edwin
    Mills, Anthony
    Cohen, Calvin
    Wohl, David
    Gallant, Joel E.
    Liu, Hui C.
    Plummer, Andrew
    White, Kirsten L.
    Cheng, Andrew K.
    Rhee, Martin S.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
  • [24] Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
    Orkin, Chloe
    Squires, Kathleen E.
    Molina, Jean-Michel
    Sax, Paul E.
    Sussmann, Otto
    Lin, Gina
    Kumar, Sushma
    Hanna, George J.
    Hwang, Carey
    Martin, Elizabeth
    Teppler, Hedy
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : 33 - 42
  • [25] Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection
    Lyseng-Williamson, Katherine A.
    Scott, Lesley J.
    CLINICAL DRUG INVESTIGATION, 2012, 32 (10) : 715 - 722
  • [26] Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection
    Katherine A. Lyseng-Williamson
    Lesley J. Scott
    Clinical Drug Investigation, 2012, 32 : 715 - 722
  • [27] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
    Cohen, Calvin
    Wohl, David
    Arribas, Jose R.
    Henry, Keith
    Van Lunzen, Jan
    Bloch, Mark
    Towner, William
    Wilkins, Edmund
    Ebrahimi, Ramin
    Porter, Danielle
    White, Kirsten
    Walker, Ivan
    Chuck, Susan
    De-Oertel, Shampa
    Fralich, Todd
    AIDS, 2014, 28 (07) : 989 - 997
  • [28] Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1
    Stirrup, Oliver
    Sterne, Jonathan
    Dunn, David T.
    Grabmeier-Pfistershammer, Katharina
    Papastamopoulos, Vasileios
    Vandenhende, Marie-Anne
    Wit, Ferdinand
    Porter, Kholoud
    Gunsenheimer-Bartmeyer, Barbara
    Jarrin, Inma
    Garcia, Federico
    Faetkenheuer, Gerd
    Obel, Niels
    Schultze, Anna
    Antinori, Andrea
    Ceccherini-Silberstein, Francesca
    Mussini, Cristina
    Chene, Genevieve
    Neesgaard, Bastian
    Castagna, Antonella
    Kouyos, Roger
    De Wit, Stephane
    Sonnerbor, Anders
    Sabin, Caroline
    Merino, Dolores
    Barger, Diana
    Phillips, Andrew
    AIDS, 2019, 33 (04) : 745 - 751
  • [29] Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naive Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934
    Margot, Nicolas A.
    Enejosa, Jeff
    Cheng, Andrew K.
    Miller, Michael D.
    McColl, Damian J.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (02) : 209 - 221
  • [30] Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment
    Wilkins, Ed L.
    Cohen, Calvin J.
    Trottier, Benoit
    Esser, Stefan
    Smith, Don E.
    Haas, Bernhard
    Brinson, Cynthia
    Garner, Will
    Chuck, Susan
    Thorpe, David
    De-Oertel, Shampa
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2016, 28 (03): : 401 - 408
12345